Skip to main content
Smart Investors Daily
SL

NASDAQ · SLGL

Sol-Gel Technologies Ltd.

Healthcare · Biotechnology

$54.08

Up+$1.09 (+2.02%)

Updated Nov 20, 2026, 10:57 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
116.7M
P/E ratio
-34.22
Dividend yield
0.00%
52-week range
$50.61 – $96.00
Volume
45.03K
Avg. volume
17.87K

Price performance · SLGL

SLGL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

SLGL closed at $54.08 after 21 trading sessions, down 19.75% for the selected period.

Last close
$54.08
Period change
-19.75%
Period low
$52.83
Period high
$69.63
Daily close
View OHLC price history
SLGL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$53.72$55.32$53.38$54.0845.03K
Nov 18, 2026$55.16$56.16$53.36$53.3630.69K
Nov 17, 2026$55.50$56.20$50.61$52.8363.53K
Nov 16, 2026$55.91$58.99$53.98$54.9684.34K
Nov 13, 2026$56.795$57.78$53.03$55.1234.91K
Nov 12, 2026$62.03$62.9998$53.56$56.2544.84K
Nov 11, 2026$62.99$63.72$62.00$63.4016.18K
Nov 10, 2026$61.37$62.80$61.00$61.509.81K
Nov 9, 2026$61.63$64.70$61.21$61.7420.81K
Nov 6, 2026$62.75$65.25$60.01$61.0128.78K
Nov 5, 2026$66.00$66.50$63.00$63.019.43K
Nov 4, 2026$63.82$67.50$63.30$66.0040.35K
Nov 3, 2026$67.59$68.00$63.81$63.8144.94K
Nov 2, 2026$68.35$68.35$63.975$65.6955.99K
Oct 30, 2026$69.49$71.9775$66.95$68.3533.52K
Oct 29, 2026$69.10$71.40$68.01$68.6624.76K
Oct 28, 2026$68.31$69.51$65.50$68.1825.64K
Oct 27, 2026$72.00$72.00$68.05$68.1938.79K
Oct 26, 2026$70.89$71.50$68.30$69.6347.64K
Oct 23, 2026$67.37$70.63$67.125$69.4557.77K
Oct 22, 2026$65.69$67.395$63.53$67.3946.23K

Latest SLGL news

The latest Smart Investors Daily articles mentioning SLGL.

SLGL research

Overview

Company profile and research snapshot.

Company profile

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$50.00
Implied upside
—
Analysts
7
SLGL recent ratings
DateFirmRatingTarget
Oct 19, 2026HC Wainwright & Co.Buy—
Oct 14, 2026Cantor FitzgeraldOverweight—
Jul 20, 2026HC Wainwright & Co.Buy—
Jun 24, 2026MizuhoOutperform—
Jan 20, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Pivotal Phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome reached last patient last visit in September 2026, with 102 of 113 enrolled patients completing the study; top-line results expected in late November 2026Sol-Gel hosted a KOL Investor Event in New York on October 14, 2026, featuring leading dermatology experts and the Gorlin Syndrome AllianceU.S. commercial readiness activities for SGT-610 continue to advance ahead of a potential regulatory submission and launch NESS ZIONA,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.